^
    2d
    Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (clinicaltrials.gov)
    P3, N=5018, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Oct 2032 --> Jan 2027
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    letrozole • anastrozole • exemestane • Soltamox (tamoxifen citrate)
    9d
    CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon） (clinicaltrials.gov)
    P3, N=2288, Not yet recruiting, Fudan University
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    HER-2 positive • ER positive • HER-2 negative • HER-2 expression • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    docetaxel • cyclophosphamide • AiRuiKang (dalpiciclib)
    16d
    Clinical and economic benefits of combined genetic and genomic testing strategies to guide treatment decisions for patients with HR+/HER2- breast cancer in the US. (PubMed, J Med Econ)
    Sensitivity analyses supported the robustness of the analysis. Compared to no testing, the full testing strategy of genetic and genomic testing was more effective at a lower cost or was cost-effective, supporting the goal to increase the survival and the quality-of-life of women with breast cancer along the cancer care continuum.
    Journal • HEOR
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    19d
    Clinical Utility of Oncotype DX Testing in Synchronous Bilateral and Unilateral Multifocal Breast Cancer. (PubMed, Ann Surg Oncol)
    Recurrence score risk-category discordance is frequent in synchronous bilateral and unilateral multifocal breast cancer and often changes adjuvant chemotherapy recommendations. Reliance on single-lesion testing risks missing clinically relevant genomic heterogeneity. Multilesion testing may be warranted in selected patients to optimize treatment selection.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HR positive • HER-2 negative • EGFR positive
    |
    Oncotype DX Breast Recurrence Score®Test
    21d
    Breast cancer staging for patients with "low-risk" disease: Are they all the same? (PubMed, Cancer)
    Prognostic stage significantly influences survival among patients with low RS. RS < 11 alone should not automatically downstage patients to PPS IA; anatomic and other nongenomic factors remain important for prognosis.
    Retrospective data • Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    Oncotype DX Breast Recurrence Score®Test
    23d
    Association between tumor-infiltrating lymphocytes and oncotype DX estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 single gene scores in hormone receptor-positive/HER2-negative breast cancer. (PubMed, Front Oncol)
    In HR+/HER2- breast cancer, tumors with lower HER2 mRNA expression exhibit higher lymphocytic infiltration, suggesting the presence of a distinct immunologically active subset. Oncotype DX single gene scores, particularly HER2, may provide information beyond recurrence risk prediction and help identify patients who may benefit from immune-modulating therapeutic strategies.
    Journal • Tumor-infiltrating lymphocyte
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 positive • HR positive • HER-2 negative • HER-2 expression • EGFR positive • HR positive + HER-2 negative • HER-2 negative + ER positive
    |
    Oncotype DX Breast Recurrence Score®Test
    25d
    Genomic and clinicopathological characteristics of low oncotype recurrent score breast cancers with subsequent metastasis. (PubMed, Histopathology)
    Using real-world CGP of tumour tissue and ctDNA, we identified key molecular features associated with endocrine resistance in patients with low RS who later developed metastases. PIK3CA mutation and other ER group-related mutations contributed to the low RS. Tissue CGP provides baseline for interpreting ctDNA, and ctDNA monitoring PIK3CA, TP53, ESR1 and other pathogenic or driver mutations in the early course of low RS cases may represent an excellent non-invasive option for identifying targets and early intervention to prevent disease progression, though a large validation study is needed.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CTNNB1 (Catenin (cadherin-associated protein), beta 1) • KMT2C (Lysine Methyltransferase 2C) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1) • EMSY (EMSY Transcriptional Repressor BRCA2 Interacting)
    |
    TP53 mutation • HR positive • HER-2 negative • PIK3CA mutation • ESR1 mutation
    |
    Oncotype DX Breast Recurrence Score®Test
    28d
    Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial (clinicaltrials.gov)
    P3, N=1978, Not yet recruiting, National Cancer Institute (NCI)
    New P3 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
    |
    ER positive • HER-2 negative • ER negative • HER-2 negative + ER positive
    |
    Oncotype DX Breast Recurrence Score®Test
    |
    Kisqali (ribociclib) • letrozole • anastrozole • exemestane
    29d
    Testing Low Dose Tamoxifen for Invasive Breast Cancer, the (LoTam) Trial (clinicaltrials.gov)
    P3, N=1156, Suspended, Alliance for Clinical Trials in Oncology | Recruiting --> Suspended
    Trial suspension
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    ER positive • HER-2 negative • HER-2 negative + ER positive
    |
    Prosigna™ Breast Cancer Prognostic Gene Signature Assay • Oncotype DX Breast Recurrence Score®Test
    |
    tamoxifen • letrozole • anastrozole • exemestane
    1m
    Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) (clinicaltrials.gov)
    P3, N=314, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Oncotype DX Breast Recurrence Score®Test
    1m
    De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) (clinicaltrials.gov)
    P3, N=1670, Recruiting, NRG Oncology | Trial primary completion date: Jan 2026 --> Apr 2026
    Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative • PGR positive
    |
    MammaPrint® • Oncotype DX Breast Recurrence Score®Test
    |
    tamoxifen • letrozole • exemestane